SLC3A2 and glioma: Furthermore, to substantiate the role of SLC3A2 in glioma pathobiology, we performed both in vivo and in vitro experiments, providing a robust experimental framework to confirm our computational prognostic assessments and to explore the therapeutic potential of targeting SLC3A2 in gliomas.